| Identification | Back Directory | [Name]
Capromorelin | [CAS]
193273-66-4 | [Synonyms]
391
CP-424
CS-1525
CP 424391
Capromorelin
CP 424391; CP-424;391
CP-424391, Capromorelin
Caprimorelin (Capromorelin)
(3aR)-3a-benzyl-2-Methyl-5-(2-Methylalanyl-O-benzyl-D-seryl)-3-oxo-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridine
N-[(2R)-1-[(3~{a}R)-3~{a}-benzyl-2-methyl-3-oxo-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-phenylmethoxypropan-2-yl]-2-amino-2-methylpropanamide
N-[(2R)-1-[(3aR)-2-Methyl-3-oxo-3a-(phenylmethyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-(phenylmethoxy)propan-2-yl]-2-amino-2-methylpropanamide
Propanamide, 2-amino-N-[(1R)-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- | [Molecular Formula]
C28H35N5O4 | [MOL File]
193273-66-4.mol | [Molecular Weight]
505.61 |
| Hazard Information | Back Directory | [Uses]
Treatment
and prevention of frailty; treatment of congestive
heart failure; treatment of catabolic illness (growth
hormone secretagogue). | [in vivo]
Capromorelin increases plasma GH levels in an anesthesized rat model, with an ED50 value less than 0.05 mg/kg iv[1].
Capromorelin shows enhanced intestinal absorption in rodent models and exhibited superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat)=65%, F(dog)=44%][1].
| [IC 50]
GHSR1a: 7 nM (Ki) |
|
|